Cronos Group Inc. (CRON) Earnings Call Transcript & Summary

August 8, 2023

Toronto Stock Exchange CA Health Care Pharmaceuticals earnings 23 min

Earnings Call Speaker Segments

Operator

operator
#1

Good morning, everyone. Victor here, serving as the conference operator for today. I'd like to extend a welcome to all of you for Cronos' second quarter 2023 earnings conference call. This call is being recorded as of today. Right now, I'll hand things over to Shayne Laidlaw from Investor Relations. Please proceed.

Shayne Laidlaw

executive
#2

Thank you, Victor, and thanks to everyone for being with us today as we go through Cronos' financial and business results for the 2023 second quarter. With me on this call are our Chairman, President, and Chief Executive Officer, Michael Gorenstein, along with our Chief Financial Officer, James Holm. This morning Cronos put out a news release announcing our financial results, and that release has been filed on our EDGAR and SEDAR profiles. That information, together with the prepared remarks, will be posted as well on our website under Investor Relations. Before handing the call to Mike, I want to remind everyone that during this call we may make forward-looking statements and refer to non-GAAP financial measures. Such forward-looking statements rest on management's current expectations and assumptions, which are subject to risks and uncertainties that could make actual results differ materially from what those forward-looking statements project. The factors that could make actual results differ materially from expectations are set out in detail in our earnings materials and in our SEC filings, which are available on our website, and by those any forward-looking statements made during this call are qualified in their entirety. Details on non-GAAP financial measures, including reconciliations to U.S. GAAP, are also available in the earnings materials posted on our website.

Shayne Laidlaw

executive
#3

Finally, throughout this conference call we will be making statements about market share information, and unless otherwise stated, all market share data comes from Hifyre. We'll now make our prepared remarks, and after that we'll move to a question and answer session. With that, I'll hand things over to Cronos' Chairman, President, and Chief Executive Officer, Michael Gorenstein.

Mike Gorenstein

executive
#4

Thanks, Shayne, and good morning, everybody. In 2023, our main priorities are to keep bringing new borderless products to market, to lift our gross margin, and to find efficiencies in operating expenses — all aimed at one shared objective: generating cash flow consistently. We put a number of steps in motion to seek out greater efficiency and to bring our business and strategic priorities back into alignment. During the second quarter of 2023, we left our U.S. CBD operations behind, and that let us cut costs while concentrating on the adult-use and medical cannabis markets. As of today, we have announced that we intend to exit our Winnipeg, Manitoba facility by the end of this year, and we expect that move to produce further OpEx savings along with better COGS in 2024. In 2023, as we said before, we expect to save $20 million-$25 million on operating expenses. Thanks to today's announcements — leaving our Winnipeg facility and putting additional operating expense cuts in place — we expect to capture incremental savings of $10 million-$15 million in 2024. Even as we carry out these efficiency-focused efforts, our attention is fixed firmly on winning in market. As of June, our Spinach edibles hold the number one ranking among edibles in Canada. Among the categories where Spinach competes — edibles, vapes, pre-rolls, and flower — it is the sole brand ranked in the top 10 by market share in Canada across all of them.

Mike Gorenstein

executive
#5

When it comes to Israel, Peace Naturals remains a leading brand, powered by our strong genetics program and our cultivation strengths. And finally, now that we've exited the U.S., our teams are focused on bringing the Lord Jones brand back into adult-use categories in Canada, and we expect to launch it in Q4 of this year. I'll now go into more depth on each of these parts of our business. After surpassing our savings goal in 2022, we raised our OpEx savings targets for this year to $20 million to $25 million, partly because of the U.S. business exit. The further cost cuts we announced today will deliver some benefit within the year, but because of when these decisions were made, they will mainly land in full year 2024, with expected incremental savings of $10 million to $15 million. The ongoing gain in free cash flow this quarter shows that our hard work to drive OpEx down and to put our industry-leading balance sheet to work for a better ROI is delivering results. Today we also announced the planned exit of our facility in Winnipeg, Manitoba. We bought this fermentation facility originally to scale up development of our highly specialized cultured cannabinoid IP. We'll keep using this IP in rare cannabinoids, but we can now do so through an asset-light approach.

Mike Gorenstein

executive
#6

We led the way — and remain alone — in fermenting cannabinoids and bringing them to market commercially in Canada. Under our successful branded portfolio approach, we'll keep concentrating on creating items that use uncommon cannabinoids so consumers get distinct effects. We expect this shift to produce meaningful savings in COGS and OpEx during 2024. In addition, we're getting the facility ready to be sold, which should bring extra cash into what is already a cash balance that leads the industry. By leaving the U.S. CBD business, we can concentrate on adult-use products and hold onto cash for the U.S. entry we plan eventually. In our view, the U.S. will someday rank among the most significant cannabis markets globally, yet keeping a CBD business is no longer something we intend to do. The best use of our resources is to stay sharply focused on borderless adult-use items we're able to sell in legal markets, and to pursue cost reductions and process efficiencies so we become cash flow positive. We recognize there is value in the Lord Jones brand, and we're eager to return Lord Jones to its adult-use origins by introducing new THC-focused products in the Canadian adult-use market later this year. Together with a refreshed visual identity for Lord Jones, our end goal is a borderless product suite sold under this brand.

Mike Gorenstein

executive
#7

We're eager to bring this product lineup to you down the road, since it will pair extremely well with our Spinach products and stand apart from competing brands currently on the market. James will cover the financial results in greater depth when he speaks. I'd like to highlight the wins for this quarter. Our industry-leading balance sheet got even stronger, with cash plus short-term investments rising by roughly $5 million compared with Q1 2023. That result came from better gross margin, reduced OpEx, strong interest income, and enhanced working capital management. Sequentially, gross margins rose by an impressive 130 basis points to 16.3% — a major victory considering the macro-driven pressure on the top line. Our investment approach keeps delivering returns, generating $12.5 million in interest income during the second quarter. We plan to carry that momentum into the back half as we capture more P&L efficiencies and additional interest income from our cash and short-term investments. Now to the business: in Canada, through the second quarter, we kept executing our plan to build a strong lineup of borderless products, with new launches as the highlight. As of June 2023, Spinach holds the number three spot among cannabis brands in Canada, and it is presently the sole cannabis brand ranked top 10 across every category it competes in — including the number one position in edibles for the second quarter of 2023.

Mike Gorenstein

executive
#8

In June, Spinach edibles products made up 14.8% of the market, and they remain the leader in edibles. Our product is incredible and keeps launching in new flavor profiles and cannabinoid blends — a perfect example of a borderless, scalable product. The edibles category is still feeling the residual impact of the chewable cannabis extracts that are now banned. As those banned products keep getting removed from the market, we expect our overall market share to recover, and we are already seeing improvement, with weekly retail sales up 15% since June. This quarter, we launched a new SOURZ by Spinach flavor — our take on the timeless summer drink, Pink Lemonade, infused with raspberry and refreshing lemonade flavors. Having just launched in late May, this product has quickly gained market share. Pink Lemonade is already number four in our portfolio and keeps rising. We're excited for adult consumers to try this new flavor this summer. In the vape category, we held a 4.1% market share in June, maintaining a number seven market share position. We will build on that momentum in the back half of 2023, with a continued push to include flavor-forward profiles and rare cannabinoids in our vapes, driving innovation while leaning on our winning formulations that consumers know and love across the portfolio.

Mike Gorenstein

executive
#9

Back in July, we introduced 3 new vapes beneath the Spinach label. These latest vapes are offered in a 1.2 g format, with flavor variants of Pink Lemonade, Peach Punch, and Strawberry Slurricane. During Q2, we rolled out a number of new items to strengthen the Spinach pre-roll lineup, among them Sonic Lemon Fuel pre-rolls plus three additional infused pre-roll products. In Q2, our brand ranked eighth by market share within pre-rolls — a meaningful gain compared with number 14 in Q4. With these recent introductions and further launches still to come, we believe we can build on that standing. Flower results remain driven by our strong genetics program and the best-in-class growing expertise at GrowCo. As of June 2023, we hold the number two position among flower brands. Three of our SKUs landed in the top 10 during the second quarter: GMO Cookies in 3.5 g and 28 g, along with our Wedding Cake, 28 g. Cultivation results at GrowCo remain solid. GrowCo posted preliminary unaudited revenue of roughly $3.6 million from non-Cronos customers in the second quarter. In addition, the credit facility Cronos extended to GrowCo earlier carries $72.4 million outstanding at present, after GrowCo repaid $2.5 million of principal in Q2.

Mike Gorenstein

executive
#10

On top of that, GrowCo paid $1.7 million in interest during Q2. GrowCo's strong financial results — which generate equity pickup, interest payments, and loan repayment for Cronos — are an essential piece of our broader financial position. Now turning to Israel: in June 2023, the Knesset Health Committee revised the cannabis rules so that certain patients can get prescriptions more easily. That new regulation is set to take effect in December 2023. For some medical conditions, patients will no longer need to secure a license approved by the Ministry of Health. Physicians will be able to prescribe cannabis to those patients directly. This makes things simpler for both patients and doctors, and it should expand access and grow the patient count. Not long after the announcement, I sat down with regulators, customers, and patients, and I'm pleased that they share my enthusiasm for the growth potential in the Israeli market and for the headway this change ought to make toward capturing it. We have consistently believed in the long-term promise of our position in Israel, since it remains among the world's largest medical programs. Last quarter, our Peace Naturals brand introduced two new pre-roll products, Wedding Rolls and Cocoa Bomba. Pre-rolls have grown into a significant and expanding segment of the Canadian market.

Mike Gorenstein

executive
#11

We're really excited to introduce this innovation into the Israeli market, where flower still holds the dominant position. Alongside the pre-roll launches, we also introduced a Space Cake dried flower product. Together with Fighters for Life — an Israeli organization that helps veterans readjust to civilian life following their military service — Peace Naturals teamed up to launch a fundraising campaign ad that ran on local TV and social media in Israel. This cause has really connected with our consumers in Israel. We're proud to stand behind this organization once again. Turning to Germany, we're excited to share that in July we signed a distribution agreement with one of the leading distributors of medical cannabis in Germany. We expect to begin shipments in the third quarter. Reentering Germany marks a significant milestone for Cronos, and we look forward to broadening our reach and building brand awareness. The recently proposed regulatory change to reschedule cannabis — so that medical cannabis is no longer labeled a narcotic — is expected to unlock significant growth in the market, and we intend to establish our Peace Naturals brand as a top brand, similar to how we executed in Israel. The successes and pivots this quarter have delivered cost savings and better positioned us to assemble a portfolio of borderless products with strategic infrastructure and global partnerships.

Mike Gorenstein

executive
#12

By bringing all of this together, along with a balance sheet that leads the industry, we're well positioned to perform in any kind of market. So with that said, I'll hand things over to James, who will walk you through the financials.

James Holm

executive
#13

Thanks, Mike, and good morning to everyone. I'll now walk through our results for the second quarter of 2023 from continuing operations, compared with the same period a year earlier. Consolidated net revenue for the second quarter came in at $19 million, which is a 12% decline versus the prior year. On a constant currency basis, consolidated net revenue fell 6% to $20.2 million. The change in revenue was mainly the result of lower cannabis flower sales in Israel, stemming from competitive activity, a slowdown in patient permit authorizations, and political unrest. In Canada, it came from an adverse price mix shift within the cannabis flower category, which drove higher excise tax payments as a percentage of revenue. Consolidated results also took a hit from the weakened Canadian dollar and Israeli shekel relative to the US dollar during the current period. Consolidated gross profit for the second quarter was $3.1 million, equal to a 16.3% gross margin, which represents a $1.2 million decrease from the prior year. That decline was mainly attributable to lower cannabis flower sales in Israel and an adverse price mix shift in cannabis flower sales in Canada. These results were partly offset by lower biomass costs. Our quarterly results in 2022 were volatile from one quarter to the next, driven by the realignment of our business, and that makes comparison on the gross margin line difficult.

James Holm

executive
#14

So with that in mind, if you look at the whole of 2022, we posted a positive gross margin of 17.8%, and then the sequential path from Q4 2022 at 5.7% and Q1 2023 at 15% gross margin through to Q2 2023, when our gross margin was a positive 16.3%, shows encouraging indications of both improvement and stability, and we plan to build on that momentum through the rest of 2023 and on into 2024. Consolidated adjusted EBITDA for the second quarter came in at $-15.9 million, which is a $0.7 million gain versus the prior year. That gain came mainly from lower general and administrative and research and development expenses. As I mentioned earlier, we raised our expected cost savings target for 2023 from $10 million-$20 million to a new range of $20 million-$25 million. Continuing this savings program, we expect that exiting the Cronos fermentation facility, together with the further OpEx reductions we announced today, will capture an incremental $10 million-$15 million in full-year savings in 2024. On the balance sheet, the company finished the quarter with roughly $841 million in cash and short-term investments, up about $4.5 million from the first quarter. Beyond maximizing the return on our cash, we received an interest payment on our GrowCo senior secured loan of $1.7 million, a principal payment of $2.5 million, and $1.3 million in payments on the Mucci promissory note, for total cash paid to Cronos by GrowCo and our JV partners of $5.5 million in Q2.

James Holm

executive
#15

With the strongest balance sheet in cannabis, we can place prudent, strategic wagers while staying firmly committed to cutting cash burn. Turning to free cash flow, which we define as operating cash flow minus CapEx, Q2 2023 came in at -$12.3 million, a 36% year-over-year improvement. If you exclude the income taxes payable tied to the one-time Altria warrant relinquishment in Q1, free cash flow improved 22% sequentially. We expect to recover the bulk of that tax payment related to the one-time Altria warrant relinquishment across the coming three years. Shifting to outlook and guidance, we expect the net change in cash — defined as cash and cash equivalents plus short-term investments — for the rest of fiscal year 2023 to decrease by less than $5 million-$10 million. That is better than our prior guidance of a decline of less than $25 million over the remaining nine months of fiscal year 2023. The company continues to expect the next net change in cash to be positive in 2024. This better cash flow trajectory will come from, among other things, ongoing gross margin gains, efforts to reduce operating expenses, and anticipated interest income of $20 million-$25 million for the remainder of fiscal year 2023.

James Holm

executive
#16

Even as we keep cutting operating expenses and managing cash flow, this quarter we decided to stop giving revenue guidance, and we are pulling the net revenue target of $100 million-$110 million for the full year 2023 that we had previously announced. No longer providing net revenue guidance is a reflection of turbulent market conditions in the markets we operate in that go beyond what we had expected before. To be specific: growing political unrest and stagnant patient growth in Israel, the decision to exit the U.S. business, and competitive activity in Canada, driven by the lingering effects of edible extracts. On top of that, foreign exchange rates have hurt our net revenue. Even with these top-line headwinds, there are a lot of wins we can point to, and I share Mike's confidence in the trajectory of the business and in our preparedness for entry into new markets as they become available. With that, I'll turn it back to Mike.

Mike Gorenstein

executive
#17

Thank you, James. In Canada and Israel, we're coming out ahead, and that's because our employees have put in tremendous effort to deliver best-in-class borderless products to the market. Among all the categories our Spinach brand competes in — flower, pre-rolled, vapes, and edibles — it is the sole brand holding a top 10 market share position in every one of them. As regulations evolve, we're confident we'll rank among the cannabis companies best positioned to gain additional market share in whatever market. Before we take questions, I'd like to establish a baseline on what falls under the Cronos umbrella and where matters stand right now. Q2 ended with $841 million in cash and equivalents and no debt. Interest income of $12.5 million was generated in Q2, and we expect to generate a further $20 million-$25 million in interest income over the rest of 2023. For June 2023, our Spinach brand holds these market share ranks. Spinach ranks number three among cannabis brands overall. It is number one in edibles, number two in flower, number eight in pre-rolled — where it is quickly taking share — and number seven in vape, where it is also gaining ground. In Israel, we have a leading medical brand, Peace Naturals, which posted $5.4 million in net revenue in Q2.

Mike Gorenstein

executive
#18

We hold a 6.3% interest in PharmaCann, among the biggest private MSOs in the U.S., and it currently sits on our books at $49 million. In Vitura, a top publicly traded Australian medical cannabis supplier, our stake is roughly 10%, valued at about $18.9 million as of the close of Q2. Our ownership of Cronos GrowCo's equity stands at 50%, and that business is profitable; GrowCo and our JV partner together paid us $5.5 million in principal and interest during Q2. At quarter end, the remaining balance on our combined loans to GrowCo and its partners came to approximately $84 million. We hold real estate and several licensed facilities, all free of any encumbrances. Finally — and this matters a great deal — we have an exclusive global partnership with Altria. When the market closed yesterday, Cronos carried a market cap of roughly $720 million and an enterprise value of approximately negative $120 million. This quarter's top line came in below what I think Cronos can deliver, yet we finished the quarter holding more cash than at the end of last quarter. If one theme has run through cannabis earnings calls over the past few quarters, it is that cash is king — and since our net cash is more than 4 times that of the nearest competitor, the crown belongs to Cronos.

Mike Gorenstein

executive
#19

Having said that, I'll now turn things over for any questions.

Operator

operator
#20

If you'd like to ask something, just hit star one one on your phone and hold until we call your name. Should you want to take your question back, hit star one one once more. We ask that you keep to a single question plus one follow-up. Kindly hold on while we put the Q&A roster together. Just a moment as we get the first question ready. Vivien Azer from Cowen is our first questioner. Your line is open.

Vivien Azer

analyst
#21

Thanks, and good morning, everyone.

Mike Gorenstein

executive
#22

Morning, everyone.

Vivien Azer

analyst
#23

Mike, I wanted to see whether we might spend a bit more time discussing the expected Canadian launch of Lord Jones, especially given what you said about volatility up in the Canadian marketplace. I've been thinking about how the brand was positioned historically in the U.S. and how you plan to position it in Canada, particularly with the difficulties at the very top end of the market. Thanks.

Mike Gorenstein

executive
#24

Absolutely, and thank you, Vivien — that's a really good question. When we look at Lord Jones, we've consistently appreciated the brand's historic standing at the premium tier, particularly within edibles. I believe we've succeeded quite well at standing apart in that segment specifically. That said, we continue to perceive openings across premium offerings more broadly when you bring genuine differentiation. Flower may prove somewhat tougher, yet we do believe a real opportunity exists, since we've put substantial effort into developing a truly additive edible format that aligns strongly with the Lord Jones name — allowing us to bring those elements together for a launch. Beyond that, considering the portfolio as a whole and where our distribution currently stands, plus the momentum behind Spinach and our capacity to draw on the ties we hold with our trade partners, along with the expertise and product innovation we've built up across the past few years, we genuinely see the chance here. Our view is that it's additive. As a rule, we're quite deliberate about which launches we ultimately choose to pursue.

Mike Gorenstein

executive
#25

Honestly, this is something I feel pretty enthusiastic about. If you consider premium, the addressable market won't be comparable to what Spinach has, but from the standpoint of margin and profitable growth, launching strikes us as a genuinely sound move, and it's a superior setting for really refining the products rather than attempting to keep items in the US that may not match what the brand will look like going forward.

Vivien Azer

analyst
#26

Yeah, that's quite reasonable. And just to build on that point, when you look at it from a distribution angle, does it make any sense to take a more selective approach to distribution so that you're protecting that brand equity, instead of pursuing, you know, distribution across the entire country?

Mike Gorenstein

executive
#27

That's a really good question. I think a lot of it—when you examine the various provinces—how deep the selling might go, you know, is going to hinge on what the store setup looks like in each particular province. Obviously, some of them, you'd expect, would perform better at the premium end. Of the major provinces in terms of population, I think it still makes sense to place the same level of focus. I think you'll still see a national launch, but as you know, we tend to do a more phased rollout and make sure that we've got the demand and the right positioning.

Vivien Azer

analyst
#28

That's clear. Appreciate it.

Operator

operator
#29

Thanks. And just a reminder — that's star one one to ask a question, star one one. Give us a moment while the Q&A gets put together. All right, since nothing else has come in from the queue, that brings today's conference call to a close. Thanks for joining us. You can disconnect at this point. Everyone, have a great day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.